◆ Market Terminal AILook up a stock

BioCryst Pharmaceuticals, Inc. (BCRX)

Healthcare · Biotechnology · Small-cap · updated October 16, 2026

NOT A BUY TODAY
What this means. BioCryst Pharmaceuticals, Inc. is an average business by our measures, its shares look cheap compared with other stocks, and its share price has been weak.
Value80
Quality51
Price trend35
Overall62
307 of 2764rank among the US stocks we score (our core model buys the top 15)
89%of US stocks we score rank below it

Scores are 0 to 100 against every US stock we track; 50 is average. Recomputed after every US market close.

The business in numbers

Fiscal year to December 2025, from the company's annual filing with the SEC.

Salesyearly sales$874.8M
Sales growthchange from the year before+94.1%
Gross marginshare of sales left after the direct cost of what it sells97.8%
Operating marginshare of sales left after running the business39.0%
Net marginshare of sales kept as profit30.2%
Return on equityprofit vs. shareholders' accounting valuen/m
Debt / equitydebt vs. shareholders' accounting valuen/m
Change in share countnegative = the company is buying back its shares+5.7%

Insider trades, last 90 days

No open-market buys or sells by its directors or officers in the last 90 days.

Higher-scoring in the same industry

Interactive lookupGet the Ledger every Monday

Not financial advice. Research and education only: the same view for everyone, with no regard to your circumstances. Past results do not predict future ones. Decide for yourself or with a licensed adviser. Terms · Privacy